Latest studies
Every paper our editors flag with a plain-language note and an evidence rating. Filter by evidence, species, or design to find what actually applies to you.
- Study · TesamorelinWeak / none
The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.
This is a small double-blind, placebo-controlled pilot trial (22 adults) of low-dose tesamorelin, a growth hormone-releasing hormone (GHRH) analog, tested for effects on cognition and brain connectivity across a spectrum from normal cognition to mild cognitive impairment. Researchers reported that 10 weeks of low-dose (1 mg) tesamorelin was not associated with statistically significant changes in the prespecified measures of body composition, cognition, sleep, or imaging. Using exploratory machine-learning analysis, the authors identified possible treatment-related differences in specific brain regions. Weigh this cautiously: the trial was a pilot, underpowered, used a lower dose than the approved 2 mg, and the imaging signals are hypothesis-generating rather than confirmatory. It sits at the periphery of tesamorelin's established evidence base, which centers on visceral-fat reduction in HIV-associated lipodystrophy.
eNeurologicalScin=—HumanSep 1, 2026 - Study · TesamorelinWeak / none
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol.
This is a study protocol, not results — a distinction that governs how to read it. TRIUMPH is a two-site, double-blind randomized trial that will test tesamorelin (a growth hormone-releasing hormone analogue) versus placebo, added to a home-based exercise program, in 100 sedentary older adults (50-80) living with HIV who are frail or at risk and carry excess abdominal fat. Tesamorelin is the intervention, so relevance to our coverage is high, and the design — randomized, placebo-controlled, blinded — is rigorous. But because this is only the trial's blueprint, there are no findings to report: outcomes on physical function, muscle content and quality, quality of life, and mitochondrial function at weeks 24 and 48 are planned, not observed. Tesamorelin's established human evidence sits in HIV-associated visceral fat reduction; extending it to physical function and frailty is a reasonable and novel hypothesis this trial will test. For readers, the value is a forward look at a well-designed study to watch (NCT06554717); no efficacy conclusions can be drawn yet.
BMJ openn=——Jul 8, 2026